Phio Pharmaceuticals Corp. (PHIO) intrinsic value & 10-year financials
Phio Pharmaceuticals Corp. (PHIO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.87
- Market cap
- $686.0K
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 3.4%
- ROIC (10-yr avg)
- 968.6%
- Free cash flow (FY2025)
- -$8.0M
PHIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.7M | — | -$8.0M | — | — |
| FY2024 | — | -$7.2M | -$9.08 | -$7.1M | — | 1041.2% |
| FY2023 | — | -$10.8M | -$5.20 | -$10.8M | — | 1297.8% |
| FY2022 | — | -$11.5M | -$10.10 | -$12.2M | — | 800.7% |
| FY2021 | — | -$13.3M | -$12.43 | -$11.9M | — | 1017.4% |
| FY2020 | $0 | -$8.8M | — | -$8.8M | — | 1191.5% |
| FY2019 | $21.0K | -$8.9M | — | -$8.7M | -42795.2% | 865.8% |
| FY2018 | $138.0K | -$7.4M | — | -$7.5M | -5336.2% | 566.0% |
| FY2017 | $15.0K | -$12.5M | — | -$9.7M | -93746.7% | — |
| FY2016 | $19.0K | -$9.0M | — | -$7.8M | -47447.4% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Phio Pharmaceuticals Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Phio Pharmaceuticals Corp. returns on capital have been average, hovering around 9.7% ROIC over the decade.
Phio Pharmaceuticals Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Phio Pharmaceuticals Corp. is modeled at 3.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-145.61 per share.